Takeda Chemical Industries of Japan is extending its European clinical research activities in the UK, which are currently organized from the Takeda Euro R&D Center in Frankfurt, Germany.
The company is opening a new UK branch office in this month, in central London. It will have a medical department with a staff of four to six initially, and be responsible for conducting clinical trial studies in the UK and Eire under assignment from and jointly with the Euro R&D Center.
Products currently in development Europe-wide include TCV-116, an angiotensin II receptor antagonist and AO-128, a new antidiabetic agent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze